McGann M, Sacco A, Barnachea L. Evaluation of Extended-Release Oxycodone Administered through Enteral Tubes for the Management of Pain in Patients with Head and Neck Cancer: A Case Series [published online ahead of print, 2021 Sep 10]. J Pain Palliat Care Pharmacother. 2021;1-6. doi:10.1080/15360288.2020.1830224

Webster L, Rauck RL. Atypical opioids and their effect on respiratory drive. J Opioid Manag. 2021;17(7):109-118. doi:10.5055/jom.2021.0648

Takemura M, Niki K, Okamoto Y, et al. Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone. Biol Pharm Bull. 2021;44(9):1286-1293. doi:10.1248/bpb.b21-00212

Überall MA, Elling C, Eibl C, et al. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry [published online ahead of print, 2021 Aug 11]. Pain Manag. 2021;10.2217/pmt-2021-0058. doi:10.2217/pmt-2021-0058

Natoli S, Carpenedo R, Chinè E, Vannicola F, Leonardis F, Dauri M. Should we be concerned when COVID-19-positive patients take opioids to control their pain? Insights from a pharmacological point of view. Eur Rev Med Pharmacol Sci. 2021;25(14):4854-4867. doi:10.26355/eurrev_202107_26399

Sloan G, Alam U, Selvarajah D, Tesfaye S. The Treatment of Painful Diabetic Neuropathy [published online ahead of print, 2021 Jul 6]. Curr Diabetes Rev. 2021;10.2174/1573399817666210707112413. doi:10.2174/1573399817666210707112413